NCT03843060已完成1 期
A Phase 1 Single Center Open-label, Non-randomized, Fixed Sequence Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of AZD9977 When Administered Alone and With Itraconazole
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Area under plasma concentration-time curve from time zero to infinity (AUC) for AZD9977
研究概览
简要总结
This is an open-label, non-randomized, fixed sequence study conducted at a single study center with primary aim to assess the pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole.
详细描述
This is an open-label, non-randomized, fixed sequence study conducted at a single study center with primary aim to assess the pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole. Two types of treatments (treatment period 1 and treatment period 2) will be administered in a fixed order separated by a washout period of 3 days or more. Treatment period 1 will be single dose of AZD9977 (Dose 1) administration, in the fed state, on Day 1 followed by at least 3 days washout period. For treatment period 2, Itraconazole will be administered daily (Dose 2) from Day 4 to Day 8 plus AZD9977 (Dose 1, fed state) will be administered as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Provision of signed and dated, written informed consent prior to any study specific procedures.
- •Healthy male and female participants of non-childbearing potential aged 18 - 55 years with suitable veins for cannulation or repeated venipuncture.
- •Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria:
- •Postmenopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle stimulating hormone (FSH) levels ≥40 mlU/ml.
- •Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
- •Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
排除标准
- •History of any clinically significant disease or disorder which, in the opinion of the PI, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study..
- •History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- •Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.
- •Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, as judged by the PI including serum potassium > 5.0 mmol/L, serum hsTnI > 25.6 pg/mL, and NT-pro-BNP > 124 pg/mL.
- •Any clinically significant abnormal findings in vital signs as specified below and as judged by the PI at screening and on admission including:
- •Systolic blood pressure (SBP) < 90 mmHg or > 140 mmHg.
- •Diastolic blood pressure (DBP) < 50 mmHg or > 90 mmHg.
- •HR < 45 or > 90 beats per minute (bpm).
- •Any clinically significant abnormalities on 12-lead ECG, as judged by the PI.
- •Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.
- •Known or suspected history of drug abuse in the last 12 months as judged by the Investigator.
- •Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or 1 month after the last visit whichever is the longest.
- •Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.
- •History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to AZD
- •Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the 3 months prior to screening.
- •Positive screen for drugs of abuse, cotinine or alcohol at screening or on each admission to the study center.
- •Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
- •Use of any prescribed or non prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half life.
- •Known or suspected history of alcohol or drug abuse or excessive intake of alcohol in the last 12 months as judged by the PI.
- •Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives.
- •Participants who have previously received AZD
- •Judgment by the PI that the participant should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
- •Vulnerable participants , e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
- •Participants with any special dietary restrictions such as participants that are lactose intolerant or are vegetarians/vegans.
- •Drugs affecting CYP3A4 (itraconazole) should be refrained from use for 3 weeks prior to study commencement and thereafter until study completion.
- •The following exclusion criterion is driven by contraindications from the proposed concomitant CYP3A4 (itraconazole) inhibitor medications: Itraconazole (Sporanox) capsules are contra-indicated in patients with known hypersensitivity to itraconazole or to any of the excipients.
研究组 & 干预措施
Single AZD9977
Experimental
During this treatment period, healthy participants will be administered with a single AZD9977 (Dose 1) dose, in the fed state, on Day 1 followed by at least 3 days washout period.
干预措施: AZD9977 (Drug)
Itraconazole + AZD9977
Experimental
During this treatment period, healthy participants will be administered with Itraconazole (Dose 2) from Day 4 to Day 8 plus will be administrated with AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole will be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
干预措施: Itraconazole (Drug)
结局指标
主要结局
Area under plasma concentration-time curve from time zero to infinity (AUC) for AZD9977
时间窗: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose
To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast) for AZD9977
时间窗: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose
To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole
Maximum observed plasma concentration (Cmax) for AZD9977
时间窗: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose
To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole
次要结局
- Time to reach Maximum Observed Plasma Concentration (tMax)(Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose)
- Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)(Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose)
- Mean residence time of the unchanged drug in the systemic circulation from time zero to infinity (MRT)(Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose)
- Terminal elimination rate constant (λz)(Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose)
- Apparent total body clearance of drug from plasmsa after extravascular administration (CL/F)(Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose)
- Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)(Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose)
- Number of participants with adverse events (AEs)(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal blood pressure (both systolic and diastolic blood pressure)(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal pulse rate(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal 12-lead Electrocardiograms (ECG)(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal physical examination findings(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Hematology- White blood cell (WBC) count(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participnats with abnormal laboratory assessments: Hematology- Red blood cell (RBC) count(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of paticipants with abnormal laboratory assessments: Hematology - Hemoglobin (Hb)(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Hematology - Hematocrit (HCT) and Reticulocyte absolute count(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular hemoglobin (MCH)(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Creatine kinase (CK)(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Creatinine(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Glucose (fasting)(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular volume (MCV)(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular hemoglobin concentration (MCHC)(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Hematology- Neutrophils absolute count(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnotmal laboratory assessments: Hematology- Lymphocytes absolute count(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Hematology- Monocytes absolute count(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Hematology- Eosinophils absolute count(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Hematology- Basophils absolute count(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Hematology- Platelets count(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Calcium, potassium, phosphate and sodium(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Liver enzymes(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Albumin(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - C reactive protein (CRP)(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Serum Clinical chemistry- Uric acid(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Serum Clinical chemistry- BUN(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Total Bilirubin (TBL)(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Indirect bilirubin(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Protein(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - High-sensitivity troponin I ((hsTnI)(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - N-terminal-pro-brain natriuretic peptide (NT-pro-BNP)(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Blood(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
- Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Glucose(From screening (Day -28) till follow-up visit (up to approximately 6 weeks))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy SubjectsHealthyNCT03836222Processa Pharmaceuticals18
撤回
1 期
A Study Exmining the Effect of Multiple Doses of Bitopertin on the Single Dose Pharmacokinetics of Midazolam in Healthy Volunteers.Healthy VolunteerNCT02019290Hoffmann-La Roche
已完成
1 期
Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult SubjectsHealthyNCT03792971Galera Therapeutics, Inc.13
已完成
1 期
Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and MidazolamDrug Interaction PotentiationNCT03126578LEO Pharma32
已完成
不适用
Evaluation of the Safety and Performance Characteristics of Mesofiller Aox for the Correction of Mild and Moderate Facial Wrinkles.Skin AgingSkin WrinklingNCT06486740Mesoestetic Pharma Group S.L.55